PE20212271A1 - Combinaciones de anticuerpos anti-ildr2 y antagonistas de pd-1 - Google Patents
Combinaciones de anticuerpos anti-ildr2 y antagonistas de pd-1Info
- Publication number
- PE20212271A1 PE20212271A1 PE2021001680A PE2021001680A PE20212271A1 PE 20212271 A1 PE20212271 A1 PE 20212271A1 PE 2021001680 A PE2021001680 A PE 2021001680A PE 2021001680 A PE2021001680 A PE 2021001680A PE 20212271 A1 PE20212271 A1 PE 20212271A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- antagonists
- combinations
- ildr2
- cdr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UN ANTICUERPO ANTI-ILDR2 O UN FRAGMENTO DEL MISMO QUE COMPRENDE LAS TRES SECUENCIAS DE CADENA PESADA DE CDR DE ACUERDO CON LAS SEC ID NO:1, SEC ID NO:2 Y SEC ID NO:3 Y LAS TRES SECUENCIAS DE CADENA LIGERA DE CDR DE ACUERDO CON LAS SEC ID NO:4, SEC ID NO:5 Y SEC ID NO:6. TAMBIEN SE REFIERE A UNA COMBINACION QUE COMPRENDE A) UN ANTICUERPO ANTI-ILDR2 O UN FRAGMENTO DEL MISMO, Y B) UN ANTAGONISTA DE PD-1 TAL COMO NIVOLUMAB O PEMBROLIZUMAB. DICHA COMBINACION ES UTIL EN EL TRATAMIENTO DE CANCER.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962832320P | 2019-04-11 | 2019-04-11 | |
| PCT/EP2020/059745 WO2020207961A1 (en) | 2019-04-11 | 2020-04-06 | Combinations of anti-ildr2 antibodies and pd-1 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20212271A1 true PE20212271A1 (es) | 2021-11-30 |
Family
ID=70224379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001680A PE20212271A1 (es) | 2019-04-11 | 2020-04-06 | Combinaciones de anticuerpos anti-ildr2 y antagonistas de pd-1 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220169736A1 (es) |
| EP (1) | EP3952910A1 (es) |
| JP (1) | JP2022528472A (es) |
| KR (1) | KR20210151808A (es) |
| CN (1) | CN113645999A (es) |
| AR (1) | AR118621A1 (es) |
| AU (1) | AU2020271352A1 (es) |
| BR (1) | BR112021020148A2 (es) |
| CA (1) | CA3136510A1 (es) |
| IL (1) | IL287093A (es) |
| MX (1) | MX2021012406A (es) |
| PE (1) | PE20212271A1 (es) |
| SG (1) | SG11202109623WA (es) |
| TW (1) | TW202104275A (es) |
| WO (1) | WO2020207961A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ563193A (en) | 2005-05-09 | 2010-05-28 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| ES2437327T3 (es) | 2007-06-18 | 2014-01-10 | Merck Sharp & Dohme B.V. | Anticuerpos para el receptor PD-1 humano de muerte programada |
| AU2008296361B2 (en) * | 2007-09-04 | 2013-04-11 | Compugen, Ltd. | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
| AU2013216320A1 (en) * | 2012-02-01 | 2014-04-03 | Compugen Ltd. | C10RF32 antibodies, and uses thereof for treatment of cancer |
| IL274751B1 (en) * | 2017-11-30 | 2024-07-01 | Bayer Ag | ILDR2 antagonists and combinations thereof |
-
2020
- 2020-04-06 AU AU2020271352A patent/AU2020271352A1/en active Pending
- 2020-04-06 KR KR1020217032165A patent/KR20210151808A/ko unknown
- 2020-04-06 EP EP20717633.0A patent/EP3952910A1/en active Pending
- 2020-04-06 PE PE2021001680A patent/PE20212271A1/es unknown
- 2020-04-06 US US17/594,269 patent/US20220169736A1/en active Pending
- 2020-04-06 BR BR112021020148A patent/BR112021020148A2/pt not_active Application Discontinuation
- 2020-04-06 WO PCT/EP2020/059745 patent/WO2020207961A1/en active Application Filing
- 2020-04-06 SG SG11202109623W patent/SG11202109623WA/en unknown
- 2020-04-06 CN CN202080027714.5A patent/CN113645999A/zh active Pending
- 2020-04-06 JP JP2021560557A patent/JP2022528472A/ja active Pending
- 2020-04-06 MX MX2021012406A patent/MX2021012406A/es unknown
- 2020-04-06 CA CA3136510A patent/CA3136510A1/en active Pending
- 2020-04-08 AR ARP200100985A patent/AR118621A1/es unknown
- 2020-04-09 TW TW109111937A patent/TW202104275A/zh unknown
-
2021
- 2021-10-07 IL IL287093A patent/IL287093A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202104275A (zh) | 2021-02-01 |
| CA3136510A1 (en) | 2020-10-15 |
| BR112021020148A2 (pt) | 2021-12-21 |
| JP2022528472A (ja) | 2022-06-10 |
| AR118621A1 (es) | 2021-10-20 |
| AU2020271352A8 (en) | 2022-04-07 |
| MX2021012406A (es) | 2022-01-19 |
| SG11202109623WA (en) | 2021-10-28 |
| WO2020207961A1 (en) | 2020-10-15 |
| CN113645999A (zh) | 2021-11-12 |
| US20220169736A1 (en) | 2022-06-02 |
| EP3952910A1 (en) | 2022-02-16 |
| IL287093A (en) | 2021-12-01 |
| KR20210151808A (ko) | 2021-12-14 |
| AU2020271352A1 (en) | 2021-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020000263A1 (es) | Conjugado de anticuerpo monoclonal contra bcma-fármaco. | |
| CU24568B1 (es) | Anticuerpo inhibidor de masp-3 | |
| PE20180927A1 (es) | Moleculas de union a lag-3 y metodos de uso de las mismas | |
| PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
| PE20191347A1 (es) | Anticuerpos procoagulantes | |
| CO2017005650A2 (es) | Anticuerpos anti-interleucina-33 | |
| PE20190208A1 (es) | Anticuerpos que reconocen tau | |
| CO2020016559A2 (es) | Anticuerpos que se dirigen al gp120 de vih y métodos de uso | |
| CO2019013935A2 (es) | Anticuerpos que se unen específicamente a pd-1 y métodos de uso | |
| EP4257613A3 (en) | Bispecific checkpoint inhibitor antibodies | |
| AR104280A1 (es) | Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos | |
| MX2016017240A (es) | Diacuerpos enlazados covalentemente que tienen inmunoreactividad con pd-1 y lag-3, y metodos de uso de los mismos. | |
| PE20120902A1 (es) | Anticuerpos anti-egfl7 humanizados | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| PE20171653A1 (es) | Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b | |
| EA201991729A1 (ru) | Антитела к tgf-бета и их применение | |
| PE20170908A1 (es) | VARIANTES DE INTERFERON a2b | |
| PE20200734A1 (es) | Anticuerpos anti-tgf-beta y su uso | |
| UY37834A (es) | Tratamiento de mh con compuestos de pirimidinadiona | |
| CO6700829A2 (es) | Moduladores novedosos y métodos de uso | |
| CL2020002600A1 (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso | |
| EA201992091A1 (ru) | Анти-c5 антитела и их применение | |
| ES2572215T3 (es) | Anticuerpo neutralizante contra el receptor de prolactina Mat3 y su uso terapéutico | |
| DOP2018000284A (es) | Anticuerpos antifactor de la coagulación xi | |
| DOP2019000064A (es) | Anticuerpo que se une específicamente a pd-1 y fragmento funcional del mismo |